ACE 2023
Alternative Names: ACE-2023Latest Information Update: 06 Sep 2022
At a glance
- Originator Acepodia
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 02 Sep 2022 ACE 2023 is available for licensing as of 02 Sep 2022. https://www.acepodia.com/partnerships/
- 02 Sep 2022 Early research in Haematological malignancies in Taiwan prior to September 2022 (Parenteral) (Acepodia pipeline, September 2022)
- 02 Sep 2022 Early research in Solid tumours in Taiwan prior to September 2022 (Parenteral) (Acepodia pipeline, September 2022)